News
Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets.
Cambridge, UK, 30 October 2018: TTP Ventus, manufacturer of the Disc Pump range of multi-award-winning micropumps, today introduced its XP Series, the latest pump products in the Company’s strategic development pipeline. The XP Series offers enhanced performance, efficiency, and a wide operational temperature range to support a more diverse range of applications across the medical, life sciences, environmental and defence sectors.
Cambridge, UK, 24 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m.
A brand-new lab facility is soon to be opening within the heart of Newcastle’s £350m urban development scheme - Newcastle Helix.
The Biosphere will provide a home for ambitious companies within life sciences and innovation, research and development. This is all part of the city’s wider commitment to support economic development and growth within the life sciences sector.
AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line.
PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy.
GiroNEX Ltd – a new Cambridgeshire-based technology spin-out – has announced today first details of a novel precision powder dispensing technology that could significantly increase the pharmaceutical industry’s ability to offer patient-specific dosing for more effective treatment of specific conditions.
Genomics England names Congenica as Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service
17 October 2018
Cambridge, UK, 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.